State-of-the-Art PaperCardiac Uses of Phosphodiesterase-5 Inhibitors
Under an Elsevier user license
open archive
Key Words
altitude sickness
cardioprotection
heart failure
high-altitude pulmonary edema
high-altitude pulmonary hypertension
pulmonary hypertension
Raynaud's phenomenon
vasodilation
Abbreviations and Acronyms
Bcl-2
B-cell lymphoma protein-2
cAMP
cyclic adenosine monophosphate
cGMP
cyclic guanosine monophosphate
CHF
congestive heart failure
HAPE
high-altitude pulmonary edema
HAPH
high-altitude pulmonary hypertension
NO
nitric oxide
PAH
pulmonary arterial hypertension
PDE5
phosphodiesterase-5
PDE5I
phosphodiesterase-5 inhibitor
Cited by (0)
Dr. Schwartz has reported that he has no relationships relevant to the contents of this paper to disclose. Dr. Levine is a consultant for Pfizer and Abbott and a speaker and consultant for Coloplast, Auxilium, and American Medical Systems. Drs. Comstock and Stecher are employees of Pfizer. Dr. Kloner has served on the Speakers' Bureau for Pfizer and Lilly.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.